Learn, Analyse & Invest
only with
only with
+91
Download Orca
Transgene Biotek Ltd.
Transgene Biotek
₹ 0.00
0.00 (0.00)%
NSE
BSE
Business Support
Small-cap - With a market cap of ₹20.84 Cr.
| EX-Date | Purpose |
|---|---|
| 29 06 2021 | Audited Results Inter alia, 1) To consider and approve the Audited Financial Results of the Company for the Quarter and Financial Year ended on 31 st March 2021. 2) To discuss and approve Service Agreement with NeoDeL Pharma Pvt Ltd. 3) To discuss and approve the change of internal auditors. 4) Any other Business matter, with the permission of the Chair. |
| 14 08 2021 | Quarterly Results |
| 12 11 2021 | Quarterly Results |
| 14 02 2022 | Quarterly Results |
| 30 05 2022 | Audited Results |
| 13 08 2022 | Quarterly Results & A.G.M. |
| 12 11 2022 | Quarterly Results |
| 14 02 2023 | Quarterly Results |
| 30 05 2023 | Audited Results |
| 05 08 2023 | Quarterly Results Inter alia, to consider :- 1) To consider and approve the closure of subsidiary company M/s. Peroral Bio Private Limited. 2) To consider and approve an extension for the date of Annual General Meeting (AGM) of the Company for the financial year 2022-23. 3) To consider and approve the appointment of M/s Geeta Serwani & Associates, as Secretarial Auditor of the Company for the financial year 2022-23. 4) To consider and approve the appointment of Ms. Vasavi & Co, as Internal Auditors of the Company for the financial year 2022-23. 5) To transact such other business as may be required. |
| 14 11 2023 | Quarterly Results & Inter alia, to consider and approve:- 2. To consider and approve the appointment of M/s.Vasavi & Co, chartered Accountants as Statutory Auditors of the Company for a period of Five years from the financial year 2023-24 upto-2027-2028, subject to the approval of members in the ensuing annual general meeting. 3. To consider and approve the appointment of M/s.Manisha Dubey, as internal auditor of the Company for financial year 2023-24. 4. To consider and approve the Notice of the 33 rd Annual General meeting for the Financial Year 2022-2023 and other related matters thereto. 5. To consider and approve Directors? Report and the annexure thereon for the Financial Year 2022-2023. 6. To transact such other business as may be required. |
| 14 02 2024 | Quarterly Results |
| 12 11 2024 | Quarterly Results & A.G.M. |
| 24 01 2025 | Quarterly Results |
| 07 05 2025 | Audited Results |
| 07 08 2025 | Quarterly Results |
| 14 11 2025 | Quarterly Results |
| 13 02 2026 | Quarterly Results |
News
No News data available
